Insider Selling: LifeStance Health Group, Inc. (NASDAQ:LFST) Insider Sells 43,705 Shares of Stock

LifeStance Health Group, Inc. (NASDAQ:LFST – Get Rating) insider Kevin Michael Mullins sold 43,705 shares of the firm’s stock in a transaction that occurred on Thursday, March 16th. The stock was sold at an average price of $6.14, for a total transaction of $268,348.70. Following the sale, the insider now owns 5,609,847 shares of the company’s stock, valued at approximately $34,444,460.58. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Kevin Michael Mullins also recently made the following trade(s):

• On Tuesday, March 14th, Kevin Michael Mullins sold 800 shares of LifeStance Health Group stock. The shares were sold at an average price of $6.11, for a total transaction of $4,888.00.
• On Wednesday, March 8th, Kevin Michael Mullins sold 122,295 shares of LifeStance Health Group stock. The shares were sold at an average price of $6.12, for a total transaction of $748,445.40.

LifeStance Health Group Stock Up 0.3 %

LifeStance Health Group stock opened at $6.27 on Friday. LifeStance Health Group, Inc. has a fifty-two week low of $4.22 and a fifty-two week high of $11.25. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.33 and a current ratio of 1.33. The firm has a 50 day moving average price of $5.31 and a 200 day moving average price of $6.06. The company has a market capitalization of $2.36 billion, a PE ratio of -10.28 and a beta of 0.59.

LifeStance Health Group (NASDAQ:LFST – Get Rating) last issued its quarterly earnings results on Wednesday, March 8th. The company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). LifeStance Health Group had a negative net margin of 25.08% and a negative return on equity of 14.08%. The company had revenue of $229.40 million during the quarter, compared to analysts’ expectations of $216.63 million. During the same quarter last year, the company posted ($0.32) EPS. The firm’s revenue was up 20.7% compared to the same quarter last year. Research analysts expect that LifeStance Health Group, Inc. will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded shares of LifeStance Health Group from an “equal weight” rating to an “overweight” rating and set a $8.00 target price for the company in a report on Friday, January 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, LifeStance Health Group presently has a consensus rating of “Moderate Buy” and an average target price of $7.85.

Hedge Funds Weigh In On LifeStance Health Group

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. boosted its position in LifeStance Health Group by 56.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 5,575 shares of the company’s stock valued at $56,000 after buying an additional 2,016 shares during the period. OLD National Bancorp IN purchased a new stake in shares of LifeStance Health Group during the 4th quarter worth $49,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of LifeStance Health Group during the 3rd quarter worth $75,000. Point72 Hong Kong Ltd purchased a new stake in shares of LifeStance Health Group during the 2nd quarter worth $63,000. Finally, Dynamic Advisor Solutions LLC purchased a new stake in shares of LifeStance Health Group during the 4th quarter worth $56,000. Hedge funds and other institutional investors own 76.49% of the company’s stock.

LifeStance Health Group Company Profile

(Get Rating)

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.